This is a prospective, non-randomised, controlled, single-surgeon, single-center post-market
clinical follow up study whereby patient undergoing routine cataract surgery will have
bilateral implantation of a recently introduced TGA (Therapeutics Goods Authority, Australia)
approved trifocal intraocular lens FineVision Evo (PhysIOL, Liège, Belgium). The primary and
secondary effectiveness data for visual acuity, defocus curves, contrast sensitivity and any
adverse events will be collected.